The prevalence of autoimmune and inflammatory disorders is growing and affects more than 80 million people today. As the demand for innovative drugs increases, the need to get compounds to market with maximum speed and efficiency becomes critical. At Kendle, we have a broad range of global and local expertise in inflammatory disease research.
We’ve conducted more than 230 clinical projects in this field since 1996, allowing us to develop an extensive global network of experienced sites as well as strong clinical research teams. We’re excited by the tremendous advances in immune-based therapies of the last decade and are keen to see them taken further.